SCHEMBL10000202

SCHEMBL10000202

c1ccc2c(Nc3ccc(Oc4ccc(Nc5cnnc6ccccc56)cc4)cc3)cnnc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 1/20 0.58
KDR P35968 1/20 0.48
TEK Q02763 1/20 0.48
HTT P42858 1/20 0.47
RAF1 P04049 1/20 0.45
MAP2K1 Q02750 1/20 0.45
LMNA P02545 1/20 0.45
POLB P06746 2/20 0.41
RAD52 P43351 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM1A O60341 1/20 0.41
GFER P55789 1/20 0.41
ACP1 P24666 8/20 0.41
SCN9A Q15858 3/20 0.40
PIN1 Q13526 1/20 0.40
RAB9A P51151 1/20 0.39
SCN5A Q14524 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
OPRM1 P35372 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1116308 0.85 KDM1A (0.48) ERBB2MAP2K1RAD52KMT2AKDM1A
SCHEMBL3759286 0.83 KDM1A (0.53) ERBB2KDRHTTRAD52KMT2A
SCHEMBL3764035 0.77 KMT2A (0.58) LMNAPOLBRAD52KMT2AKDM1A
SCHEMBL10000194 0.76 ERBB2 (0.94) ERBB2KDRTEKHTTRAD52
SCHEMBL13056988 0.76 ABCG2 (0.55) LMNAPOLBKMT2AGFERMAPT
SCHEMBL21863308 0.75 NPY5R (0.54) HTTLMNARAB9AMAPT
SCHEMBL18879049 0.74 GPR3 (0.44) LMNAKDM1ARAB9AKDM4EMAPT
SCHEMBL1387165 0.74 ERBB2 (1.00) ERBB2KDRTEKHTTRAF1
SCHEMBL4739613 0.73 FADS1 (0.63) ERBB2KMT2AACP1RAB9AKDM4E
SCHEMBL1116019 0.73 EGFR (0.63)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518965-B2 Compositions and methods for treating cancer TRUSTEES OF DARTMOUTH COLLEGE (US) 2013-08-27 US disclosed
US-8518965-B2 Compositions and methods for treating cancer TRUSTEES OF DARTMOUTH COLLEGE (US) 2013-08-27 US disclosed
US-20120165365-A1 Compositions and Methods for Treating Cancer TRUSTEES OF DARTMOUTH COLLEGE (US) 2012-06-28 US disclosed
US-20120165365-A1 Compositions and Methods for Treating Cancer TRUSTEES OF DARTMOUTH COLLEGE (US) 2012-06-28 US disclosed
WO-2011016952-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER TRUSTEES OF DARTMOUTH COLLEGE (US) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165365-A1 Compositions and Methods for Treating Cancer MKI67, DCX, NES ERBB2 305/4885KDR 2824/4885TEK 1710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.